NCT03290937View on ClinicalTrials.gov

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Metastatic Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8
Interventions
BIOLOGICAL

Cetuximab

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

OTHER

Pharmacodynamic Study

Correlative studies

BIOLOGICAL

Utomilumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER